Overexpressed PLAGL2 transcriptionally activates Wnt6 and promotes cancer development in colorectal cancer

• Published in: Oncology reports Vol. 41; no. 2; pp. 875 - 884
• Main Authors: Li, Nanpeng, Li, Daojiang, Du, Yuheng, Su, Chen, Yang, Chunxing, Lin, Changwei, Li, Xiaorong, Hu, Gui
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.02.2019; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Care and treatment; Cloning; Colorectal cancer; Development and progression; Gene expression; Genes; Genetic aspects; Health aspects; Laboratory animals; Medical research; Protein expression; Proteins; Studies; Transcription factors; Tumors; United States > US; China
• ISSN: 1021-335X; 1791-2431
• DOI: 10.3892/or.2018.6914

Researchers hold the view that PLAGL2 is overexpressed in many malignancies and that it can promote tumor proliferation, migration, invasion and self‑renewal; however, there is no evidence revealing a relationship between PLAGL2 and colorectal cancer (CRC). In the present study, genes that are overexpressed in CRC were screened using the COSMIC database and GEPIA database and the expression of PLAGL2 in carcinoma tissues and pericarcinomatous tissues was detected by RT‑qPCR and western blot assays. A Cell Counting Kit‑8 assay, a cell cycle analysis experiment and a xenograft model were used to explore the influence of PLAGL2 on CRC after knocking down PLAGL2 expression in HCT116 and SW480 cells. Using ChIP assays and Dual‑Luciferase Reporter assays, the promoter regions to which PLAGL2 binds were discovered. It was observed that PLAGL2 was overexpressed in colorectal cancer and that it influenced the colorectal cancer cell cycle and promoted colorectal cancer proliferation in vivo and in vitro. The expression of some genes in the Wnt/β‑catenin pathway, were downregulated after knocking down the expression of PLAGL2; Wnt6 was altered the most. PLAGL2 could bind to the promoter region of Wnt6 and promote its expression. These results indicated that PLAGL2 was overexpressed in CRC as a proto‑oncogene and that it could active the Wnt/β‑catenin pathway as a transcription factor by binding with the promoter region of Wnt6. PALGL2 was revealed to play an important role in colorectal cancer and may be a new therapeutic target for targeted medicine.